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##BACKGROUND We reported favorable 1-year outcomes in patients unsuitable for surgery who underwent self-
expanding transcatheter aortic valve replacement (TAVR) compared with an objective performance goal. Longer-term
outcomes in these patients are not known.
OBJECTIVES This study sought to evaluate the 2-year safety and efﬁcacy in patients with severe aortic stenosis (AS) at
extreme risk of surgery treated with self-expanding TAVR.
METHODS We performed a prospective, multicenter, controlled, nonrandomized investigation of self-expanding TAVR
in patients with severe AS and prohibitive surgical risk. We report the 2-year clinical outcomes in these patients.
RESULTS A total of 489 extreme-risk patients were treated transfemorally with a self-expanding aortic bioprosthesis at
41 centers. The rate of all-cause mortality or major stroke was 38.0% at 2 years (all-cause mortality, 36.5%; major
stroke, 5.1%). The rates of all-cause mortality, cardiovascular mortality, and major stroke were 36.6%, 26.2%, and 5.1%,
respectively, at 2 years. Between 1 and 2 years, the incremental all-cause mortality, cardiovascular mortality, and major
stroke rates were 12.3%, 7.9%, and 0.8%, respectively. Multivariable predictors of all-cause mortality at 2 years included
the presence of coronary artery disease and admission from an assisted living center. A Society of Thoracic Surgeons score
>15% was also predictive of 2-year all-cause mortality. At 2 years, 94% of patients had New York Heart Association
functional class I or II symptoms. The frequency of moderate or severe paravalvular regurgitation (4.3% at 1 year;
4.4% at 2 years) was unchanged between the ﬁrst and second year.
CONCLUSIONS Patients with severe AS at extreme surgical risk treated with self-expanding TAVR continued to show
good clinical outcomes and hemodynamic valve performance at 2 years. The presence of comorbid conditions rather than
valve performance affected 2-year outcomes in these patients. (Safety and Efﬁcacy Study of the Medtronic CoreValve
System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic
Valve Replacement; NCT01240902) (J Am Coll Cardiol 2015;66:1327–34) © 2015 by the American College of Cardiology
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TABLE 1 Baseline Clinical Characteristics and Comorbidities
(N ¼ 489)
Age, yrs 83.2  8.7
Men, % 47.9 (234/489)
Society of Thoracic Surgeons Predicted Risk
of Mortality, %
10.3  5.5
<10 55.6 (272/489)
10–15 27.2 (133/489)
>15 17.2 (84/489)
Logistic euroSCORE, % 22.6  17.1
New York Heart Association functional class III/IV 91.8 (449/489)
ABBR EV I A T I ON S
AND ACRONYMS
AS = aortic stenosis
NYHA = New York Heart
Association
STS-PROM = Society for
Thoracic Surgery Predicted Risk
of Mortality
TAVR = transcatheter aortic
valve replacement
Dr. Yakubo
an Advisor
patents fro
Board for M
Biomedical
speaker fo
Edwards Li
serves as an
Surgery Ad
Jude Medic
is an emplo
serves as a
Medical, an
have no rel
Listen to th
Manuscript
Yakubov et al. J A C C V O L . 6 6 , N O . 1 2 , 2 0 1 5
Long-Term Outcomes After TAVR S E P T E M B E R 2 2 , 2 0 1 5 : 1 3 2 7 – 3 4
1328P atients with severe symptomaticaortic stenosis (AS) deemedunsuitablefor surgery have an estimated 50.0%
mortality at 1 year without valve replacement
(1). Transcatheter aortic valve replacement
(TAVR) using balloon-expandable (1) and
self-expanding (2) bioprostheses has become
standard of care in these patients, who often
have signiﬁcant comorbidities, frailties, and
disabilities that affect their long-term prog-Diabetes mellitus 41.5 (203/489)
Insulin controlled 18.4 (90/489)
Cardiac history
Previous stroke 13.7 (67/488)nosis (3). Late outcomes after TAVR have been re-
ported (4–7), but there is limited information about
late survival in patients deemed to be at extreme
risk of surgery (8,9).Coronary artery disease 81.8 (400/489)
Previous coronary artery bypass graft 39.5 (193/489)
Previous percutaneous coronary intervention 37.0 (181/489)
Previous balloon artic valvuloplasty 20.4 (100/489)
Prohibitive anatomy
Severe aortic calciﬁcation 17.2 (84/488)
Hostile mediastinum 11.9 (58/488)
Comorbidities
Severe chronic lung disease 23.5 (115/489)
Home oxygen 29.9 (146/489)
Charlson Comorbidity Index 5.3  2.3
Frailty
Anemia with previous transfusion 22.8 (108/473)
Albumin <3.3 g/dl 18.2 (88/484)
5-m gait speed >6 s 84.2 (283/336)
Disabilities
Assisted living 27.6 (135/489)
$2 Katz ADL deﬁcits 20.9 (102/489)
Wheelchair bound 16.6 (81/489)
Values are mean  SD or frequency, % (n/N).
ADL ¼ activities of daily living; euroSCORE ¼ European System for
Cardiac Operative Risk Evaluation.
SEE PAGE 1335The CoreValve US Extreme Risk Pivotal Trial eval-
uated patients deemed unsuitable for surgery by 2
cardiac surgeons and 1 interventional cardiologist (2).
A total of 489 patients underwent implantation with
self-expanding TAVR by means of an iliofemoral ac-
cess approach (2). Despite signiﬁcant concomitant
morbidities, the rate of 1-year all-cause mortality and
major stroke at 1 year was superior to a rigorously
deﬁned objective performance goal (2). The self-
expanding aortic bioprosthesis provided sustained
improvement in the aortic valve effective oriﬁce area,
a reduction in the aortic valve gradient, and an
overall improvement in New York Heart Association
(NYHA) functional class (2). Our objective in this
study was to evaluate the 2-year clinical outcomes in
these patients.
METHODS
PATIENT ENROLLMENT AND STUDY DESIGN. De-
tailed patient enrollment criteria, inclusion and
exclusion criteria, and study methods have been re-
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TABLE 2 Clinical Outcomes at 1 and 2 Years After Self-Expanding TAVR
1 Year 2 Years
Death from any cause or major stroke 127 (26.0) 185 (38.0)
Death
Any cause 119 (24.3) 178 (36.6)
Cardiovascular 88 (18.3) 122 (26.2)
Stroke 31 (7.0) 37 (8.6)
Major 19 (4.3) 22 (5.1)
Minor 14 (3.2) 17 (4.1)
Myocardial infarction 9 (2.0) 12 (2.8)
Reintervention 8 (1.8) 8 (1.8)
Life-threatening or disabling bleeding 85 (18.0) 96 (21.1)
Major vascular complications 41 (8.4) 41 (8.4)
Valve thrombosis 0.0 0.0
Endocarditis 5 (1.3) 6 (1.6)
Device embolization/migration 1 (0.2) 1 (0.2)
Permanent pacemaker 124 (26.4) 132 (28.8)
Values are number of patients with event (Kaplan-Meier estimated rates).
TAVR ¼ transcatheter aortic valve replacement.
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1329valve velocity >4.0 m/s were eligible. Patients were
considered to be at extreme risk if they were deter-
mined to have a 50.0% or greater risk for mortality or
irreversible morbidity at 30 days with surgical
replacement (2). Baseline assessment included calcu-
lation of risk using the Society of Thoracic Surgery
Predictors of Mortality (STS-PROM) (10) and logistic
euroSCORE (European System for Cardiac Operative
Risk Evaluation) (11), the Charlson Comorbidity Index
(12), and assessments of frailty using 5-m gait speed
(13) and disability using the Katz Activities of Daily
Living (14).
The CoreValve US Extreme Risk Pivotal Trial was a
prospective, multicenter, controlled, nonrandomized,
single-arm clinical study performed at 41 clinical
sites in the United States (2). The responsible insti-
tutional review boards approved the study protocol,
and written informed consent was obtained from
all patients. The sponsor (Medtronic, Minneapolis,CENTRAL ILLUSTRATION Long-Term Outcomes After TAVR: Kaplan-Meier Estimates of All-Cause and Cardiovascular Mortality
Through 2 Years
Yakubov, S.J. et al. J Am Coll Cardiol. 2015; 66(12):1327–34.
(Inset) Landmark survival analysis of all-cause and cardiovascular mortality for the ﬁrst year after TAVR for all patients (left) and during the second year after TAVR for
patients alive at 1 year (right). TAVR ¼ transcatheter aortic valve replacement.
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1330Minnesota), funded the study and, along with the
study Steering Committee, designed the study.
The study sponsor was responsible for selection
of the clinical sites, monitoring of the data, and
management of the case report forms and statistical
analyses. An independent Clinical Events Committee
adjudicated all major adverse clinical events. The
primary author (S.J.Y.) and Co-Principal Investigators
of the CoreValve US Pivotal Trials (J.J.P. and D.H.A.)
drafted the initial manuscript. All authors contributed
to this manuscript and made the decision to submit it
for publication.
STUDY ENDPOINTS. The attempted iliofemoral
implant population was the primary analysis group
(2). All-cause mortality or stroke was assessed at 2
years. Major and minor strokes were deﬁned using
Valve Academic Research Consortium 1 criteria (15).
Valve Academic Research Consortium 1 criteria also
were used to deﬁne major adverse cardiovascular and
cerebral events that comprised all-cause death,
myocardial infarction, all stroke, and reintervention
to alter, adjust, or replace a previously implanted
valve (15). Symptom status at 2 years was assessed
using the NYHA functional classiﬁcation system.
ECHOCARDIOGRAPHIC ANALYSIS. Echocardiograms
were collected at 1 and 2 years and were interpreted
by a central laboratory (Mayo Echocardiography Core
Laboratory, Rochester, Minnesota). Prosthetic valve
dysfunction and periprocedural aortic regurgitation
were determined using Valve Academic Researcheier Estimates of Major Stroke Through 2 Years
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lysis for the ﬁrst year after TAVR for all patients (left) and during the
VR for patients alive at 1 year (right). TAVR ¼ transcatheter aorticConsortium 1 criteria (15). Aortic valve oriﬁce area and
mean gradient were compared at 1 and 2 years.
STATISTICAL ANALYSIS. Categorical variables were
compared using the Fisher exact test. Continuous
variables were presented as mean  SD and compared
with the Student t test. The Kaplan-Meier estimate and
its 95% conﬁdence interval were summarized for each
subgroup. The difference between subgroups was
compared using Cox regression with subgroup as a
factor and the time to event endpoint as the
outcome. All testing used a 2-sided alpha level of
0.05. Multivariable predictors of 2-year all-cause
mortality were identiﬁed from univariable predictors
with p < 0.05. Stepwise multivariable analyses were
performed. The signiﬁcance-level thresholds for entry
and exit of independent variables were set at 0.10. All
statistical analyses were performedwith SAS software,
version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
PATIENT FLOW AND DEMOGRAPHICS. A total of 489
patients underwent attempted iliofemoral self-
expanding TAVR at 41 U.S. centers between
February 2011 and August 2012; 486 patients were
implanted with a self-expanding bioprosthesis (2).
Between 1 and 2 years, 58 patients died, and 2 pa-
tients withdrew from the study. Two-year follow-up
was available for 289 of 307 patients (94.1%).
Clinical characteristics for the attempted implant
population are shown in Table 1. The mean age was
83.2  8.7 years; 47.9% were men; 81.8% had coronary
artery disease, and 27.6% were in an assisted living
facility. The mean STS-PROM was 10.3%  5.5% and
>15% in 17.2% of patients. Nearly 92% of patients
experienced NYHA functional class III or IV symptoms.
CLINICAL OUTCOMES. Two-year clinical outcomes
are shown in Table 2. The Kaplan-Meier rate of 2-year
all-cause mortality or major stroke in the attempted
iliofemoral implant population was 38.0% with a
2-sided upper 95% conﬁdence interval of 42.6%.
Two-year Kaplan-Meier rates were 36.6% for all-cause
mortality and 26.2% for cardiovascular mortality
(Central Illustration); the incremental rates between
year 1 and year 2 were 12.3% for all-cause mortality
and 7.9% for cardiovascular mortality. Causes of death
during year 2 are listed in the Online Table 1. The rate
of major stroke at 2 years was 5.1% (Figure 1), with a
difference in the rates at 1 and 2 years of 0.8%. Uni-
variable predictors for 2-year all-cause mortality are
shown in Table 3 (Figures 2A to 2C). Multivariable
predictors of all-cause mortality at 2 years included
the presence of coronary artery disease (p ¼ 0.002),
and admission from an assisted living center
FIGURE 2 Kaplan-Meier 2-Year All-Cause Mortality or Major Stroke Estimates for
Select Subgroups
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All-cause mortality to 2 years by (A) the presence of CAD; (B) residing in an assisted living
facility before undergoing TAVR; and (C) by STS risk severity. CAD¼ coronary artery disease;
STS ¼ Society of Thoracic Surgeons; TAVR ¼ transcatheter aortic valve replacement.
TABLE 3 All-Cause Mortality or Major Stroke for
Select Subgroups
No. of
Patients
All-Cause
Mortality or
Major Stroke p Value*
Sex 0.16
Male 255 35.1 (29.2–40.9)
Female 234 41.2 (34.9–47.6)
Age, yrs 0.41
#85 263 36.7 (30.9–42.5)
>85 226 39.6 (33.2–46.0)
New York Heart Association
functional class
II 40 30.0 (15.8–44.2)
III 313 38.3 (32.9–43.7) 0.35
IV 136 39.8 (31.6–48.1) 0.31
Left ventricular ejection
fraction, %
0.09
$40 404 36.4 (31.7–41.1)
<40 83 45.8 (35.1–56.5)
STS score, %
<10 272 35.9 (30.1–41.6)
10–15 133 34.7 (26.6–42.8) 0.84
>15 84 50.4 (39.7–61.2) 0.01
Hypertension 0.25
Yes 441 39.0 (34.4–43.6)
No 48 29.2 (16.3–42.0)
Diabetes 0.41
Yes 203 40.0 (33.3–46.8)
No 286 36.6 (31.0–42.3)
Chronic lung disease/COPD 0.36
Yes 288 40.1 (34.4–45.8)
No 201 35.0 (28.4–41.6)
Peripheral vascular disease 0.17
Yes 171 41.7 (34.3–49.1)
No 315 35.8 (30.4–41.1)
Previous stroke 0.57
Yes 67 40.3 (28.6–52.0)
No 421 37.8 (33.1–42.4)
Previous myocardial infarction 0.07
Yes 151 43.8 (35.8–51.7)
No 338 35.4 (30.3–40.6)
Coronary artery disease 0.0015
Yes 400 41.5 (36.7–46.4)
No 89 22.5 (13.8–31.1)
Assisted living <0.0001
Yes 135 50.5 (42.1–59.0)
No 315 33.3 (28.3–38.2)
Values are n or Kaplan-Meier rates (95% conﬁdence interval). *Proportional
hazard models.
COPD ¼ chronic obstructive pulmonary disease; STS ¼ Society of Thoracic
Surgeons.
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1331(p ¼ 0.0001). An STS-PROM score >15% was also pre-
dictive of 2-year all-cause mortality (p ¼ 0.07). Coro-
nary artery disease was deﬁned as the presence of
at least 1-vessel disease or having previous coronary
artery bypass grafting or a previous percutaneous
coronary intervention.Improvement in symptom status was still present
at 2 years after self-expanding TAVR. Compared with
baseline symptoms, 92.0% of patients improved at 2
years by at least 1 NYHA functional class, and 58.0%
FIGURE 3 NYHA Functional Classiﬁcation Through 2 Years
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1332improved by at least 2 classes (Figure 3). An additional
8 patients (2.4%) required a permanent pacemaker
between the ﬁrst and second year after TAVR
(Table 2). There was no effect on 2-year survival for
patients with or without a pacemaker (38.5% vs.
35.0%; log-rank p ¼ 0.55).
ECHOCARDIOGRAPHIC FINDINGS. Aortic valve ori-
ﬁce area (1.88 cm2 at 1 year and 1.86 cm2 at 2 years;
p ¼ 0.43) and mean gradient (8.86 mm Hg at 1 year
and 8.70 mm Hg at 2 years; p ¼ 0.13) were unchanged
at 2 years (Figure 4). The rates of moderate para-
valvular aortic regurgitation were similar at 1 and 2
years (Figure 5).emodynamics Over Time
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dient (blue) and effective oriﬁce area (red) remain consistent through
epresent SDs.DISCUSSION
Our study shows that the good survival and low
stroke rates at 1 year associated with the self-
expanding TAVR in patients deemed unsuitable for
surgery were sustained 2 years after the procedure
(Central Illustration, Figure 1). Our study also showed
that the improvement in aortic valve effective oriﬁce
area and reduction in the aortic valve gradient was
maintained and that improvement in functional class
persisted in patients undergoing self-expanding
TAVR. We also found that the degree of paraval-
vular regurgitation remained unchanged over the
second year after the procedure. Longer-term mor-
tality was most inﬂuenced by the presence of coro-
nary artery disease and disability requiring assisted
living.
MORTALITY AND MAJOR STROKE. Left untreated in
patients deemed unsuitable for surgery, severe AS is
associated with an all-cause mortality rate of 50.0%
at 1 year (1) and 68.0% at 2 years (8). Both balloon-
expandable (1) and self-expanding bioprostheses (2)
improve survival in these patients. We previously
reported a rate of 1-year all-cause mortality and major
stroke of 26.0% (95% upper conﬁdence bound: 29.9%)
in extreme-risk patients undergoing self-expanding
TAVR, which was signiﬁcantly lower than an objec-
tive performance goal of patients with medical ther-
apy alone (43.0%; p < 0.0001) (2). We now report an
increase in all-cause mortality from 24.3% at 1 year to
36.6% at 2 years with an incremental increase in all-
cause mortality in the second year of 12.3%, similar
to the second-year mortality rate in the PARTNER B
(Placement of Aortic Transcatheter Valve Trial B) of
18.2% (6). Late deaths in the PARTNER B were
attributable to extensive comorbidities, as reﬂected
in a worsened outcome in patients with an STS-PROM
>15.0% (8). Our study also found a relationship be-
tween STS-PROM >15% and late mortality, and we
identiﬁed that severe disability, as assessed by
admission from an assisted living facility also wors-
ened prognosis with a untoward 2-year mortality rate
(50.5% vs. 33.3% in patients admitted from home for
TAVR: p < 0.001).
Strokes occur in approximately 3.0% to 4.0% of
patients after TAVR (16). With careful neurological
examination before and after TAVR, we reported low
major stroke rates at 30 days (2.3%) and 1 year (4.3%)
(2). The current study also found a low (1.6%) stroke
rate in the second year after TAVR, similar to the 2.6%
increase in stroke in the second year in PARTNER B
(6). Although we did not characterize the type of
stroke in our study, hemorrhagic strokes occurred
most often after 30 days in the PARTNER B (8). Due to
FIGURE 5 Degree of Paravalvular Regurgitation
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1333the occasional occurrence of atrial ﬁbrillation after
TAVR and the higher risk of bleeding complications
in the elderly population, a careful balance is needed
to optimize anticoagulation in this population of
patients.
We observed a durable improvement in symptom
status associated with self-expanding TAVR in our
patients, with 94.0% of patients reporting NYHA
functional class I or II symptoms at 2 years. This
symptomatic improvement at 2 years in inoperable
patients treated with TAVR was also found in the
PARTNER B with 83.1% of patients having NYHA
functional class I or II symptoms (8).
PARAVALVULAR AORTIC REGURGITATION. Signiﬁcant
residual paravalvular regurgitation is an important
prognostic ﬁnding after TAVR (17,18). Predictors
of paravalvular regurgitation include implantation
depth, aortic valve area (17), annular size (17–19),
presence of severe calciﬁcation (17,20,21), and the use
of computed tomography imaging to guide valve
sizing (22,23). We previously reported paired analyses
that showed a reduction in the frequency of moder-
ate or severe paravalvular regurgitation during the
ﬁrst year after self-expanding TAVR (from 10.7% at
discharge to 4.2% at 1 year; p ¼ 0.004) (2). We hy-
pothesized that the mechanism of this improvement
resulted from annular remodeling due to appropriate
valve sizing on the basis of multidetector computed
tomography imaging (19,24). In the current report,
we found that the frequency of moderate para-
valvular regurgitation remained stable from 1 to 2
years (4.3% to 4.4%, respectively) (Figure 5). Longer-
term studies in a larger number of patients are
needed to understand the complex relationship be-
tween moderate paravalvular regurgitation and late
mortality.
HEMODYNAMIC FINDINGS. We found no evidence
of valve degeneration in the second year after self-
expanding TAVR in our study, and there were no
cases of valve thrombosis. There was no signiﬁcant
change in the aortic valve effective oriﬁce area or
increase in the aortic valve gradients in the second
year after self-expanding TAVR. This is similar to
hemodynamic reports by others (4,8). Although
the 2-year timeframe is short for the identiﬁcation
of structural deterioration of the self-expanding
bioprosthesis, it is reassuring that there is no
evidence of early failure in this population of
patients.
STUDY LIMITATIONS. We did not pre-specify an
objective performance goal for the composite of all-
cause mortality or major stroke in our study
beyond 1 year, and there is no active control groupfor our extreme-risk patients. Our predictor model
for later term mortality was not pre-speciﬁed, and
identiﬁed predictors should be considered explor-
atory for larger analyses. The presence of coronary
artery disease was based on a simple deﬁnition and
did not include detailed ischemia scoring or speciﬁc
vessel stenosis.
CONCLUSIONS
In patients with AS at extreme risk with surgical
aortic valve replacement, iliofemoral placement of
a self-expanding transcatheter bioprosthesis was
shown to safe and effective through 2 years. Longer-
term mortality was most inﬂuenced by the presence
of coronary artery disease and disability. Hemody-
namic improvements in aortic valve area and mean
gradients were maintained at 2 years, and the rates
of moderate or severe paravalvular regurgitation
remained unchanged over the second year after the
procedure. We conclude that self-expanding TAVR
is beneﬁcial in patients with AS without surgical
options.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Patients
with severe AS facing a high risk of death or major com-
plications with surgical valve replacement who undergo
TAVR with self-expanding prostheses exhibit sustained
improvement in valve function and clinical outcomes
after 2 years.
COMPETENCY IN PATIENT CARE AND PROCE-
DURAL SKILLS: The main determinants of clinical out-
comes during the ﬁrst 2 years after TAVR in patients with
severe, symptomatic AS at high risk of early operative
mortality are comorbid medical conditions.
TRANSLATIONAL OUTLOOK: More work is needed to
deﬁne the speciﬁc diseases, conditions, and other factors
contributing to frailty and disability as they relate to
long-term outcomes after TAVR. These efforts could lead
to the development and validation of a clinical risk pre-
diction instrument to guide selection of patients for this
procedure.
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